U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H13F6O5.Na
Molecular Weight 482.3051
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TECARFARIN SODIUM

SMILES

[Na+].CC(OC(=O)C1=CC=C(CC2=C([O-])C3=CC=CC=C3OC2=O)C=C1)(C(F)(F)F)C(F)(F)F

InChI

InChIKey=DTAROZQXDYVCQR-UHFFFAOYSA-M
InChI=1S/C21H14F6O5.Na/c1-19(20(22,23)24,21(25,26)27)32-17(29)12-8-6-11(7-9-12)10-14-16(28)13-4-2-3-5-15(13)31-18(14)30;/h2-9,28H,10H2,1H3;/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C21H13F6O5
Molecular Weight 459.3153
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Tecarfarin (also known as ATI-5923), an anticoagulant, is a vitamin K reductase antagonist. Tecarfarin is participating in phase III clinical trials for the treatment of thromboembolism and thrombosis. On March 11, 2019, Espero BioPharma Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for tecarfarin for the prevention of systemic thromboembolism of cardiac origin. Tecarfarin is metabolized by esterases, escaping metabolism by the cytochrome P450 system and thereby avoiding cytochrome P450-mediated drug-drug or drug-food interactions as well as genetic variations found in the cytochrome P450 system.

Approval Year

Targets
PubMed

PubMed

TitleDatePubMed
Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs.
2009 Nov
The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation.
2009 Sep 22
Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants.
2011 Apr
Patents

Sample Use Guides

Tecarfarin will be administered and dose adjusted by the investigator. Dose adjustments will be made in accordance with a target INR range pre-specified by the investigator
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:25:45 GMT 2023
Edited
by admin
on Fri Dec 15 15:25:45 GMT 2023
Record UNII
G7MLG4D955
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TECARFARIN SODIUM
USAN   WHO-DD  
USAN  
Official Name English
BENZOIC ACID, 4-((4-HYDROXY-2-OXO-2H-1-BENZOPYRAN-3-YL)METHYL)-, 2,2,2-TRIFLUORO-1-METHYL-1-(TRIFLUOROMETHYL)ETHYL ESTER, SODIUM SALT
Common Name English
Tecarfarin sodium [WHO-DD]
Common Name English
60-TIS-99
Code English
ATI-5923 SODIUM SALT
Code English
SODIUM 2-OXO-3-(4-((2,2,2-TRIFLUORO-1-METHYL-1-(TRIFLUOROMETHYL)ETHOXY)CARBONYL)BENZYL)-2H-CHROMEN-4-OLATE
Systematic Name English
60 TIS 99
Code English
TECARFARIN SODIUM [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C263
Created by admin on Fri Dec 15 15:25:45 GMT 2023 , Edited by admin on Fri Dec 15 15:25:45 GMT 2023
Code System Code Type Description
PUBCHEM
44201125
Created by admin on Fri Dec 15 15:25:45 GMT 2023 , Edited by admin on Fri Dec 15 15:25:45 GMT 2023
PRIMARY
CAS
1004551-83-0
Created by admin on Fri Dec 15 15:25:45 GMT 2023 , Edited by admin on Fri Dec 15 15:25:45 GMT 2023
PRIMARY
SMS_ID
300000044540
Created by admin on Fri Dec 15 15:25:45 GMT 2023 , Edited by admin on Fri Dec 15 15:25:45 GMT 2023
PRIMARY
NCI_THESAURUS
C152524
Created by admin on Fri Dec 15 15:25:45 GMT 2023 , Edited by admin on Fri Dec 15 15:25:45 GMT 2023
PRIMARY
EPA CompTox
DTXSID20143302
Created by admin on Fri Dec 15 15:25:45 GMT 2023 , Edited by admin on Fri Dec 15 15:25:45 GMT 2023
PRIMARY
FDA UNII
G7MLG4D955
Created by admin on Fri Dec 15 15:25:45 GMT 2023 , Edited by admin on Fri Dec 15 15:25:45 GMT 2023
PRIMARY
USAN
UU-116
Created by admin on Fri Dec 15 15:25:45 GMT 2023 , Edited by admin on Fri Dec 15 15:25:45 GMT 2023
PRIMARY
ChEMBL
CHEMBL2105664
Created by admin on Fri Dec 15 15:25:45 GMT 2023 , Edited by admin on Fri Dec 15 15:25:45 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY